To identify genetic variants that confer the risk of Graves' disease (GD) in the Japanese population, we conducted a two-stage genome-wide association study (GWAS) using 1119 Japanese individuals with GD and 2718 unrelated controls, and a subsequent replication study using independent 432 GD cases and 1157 controls. We identified 34 single nucleotide polymorphisms (SNPs) to be significantly associated with GD in the GWAS phase. Twenty-two out of 34 SNPs remained positive in the replication study. All 22 SNPs were located within the major histocompatibility complex (MHC) locus on chromosome 6p21. No strong long-range linkage disequilibrium (LD) was observed among the 22 SNPs, indicating independent involvement of multiple loci within the MHC with the risk of GD. Multivariate stepwise logistic regression analysis selected rs3893464, rs4313034, rs3132613, rs4248154, rs2273017, rs9394159 and rs4713693, as markers for independent risk loci for GD. The analysis of LD between these seven SNPs and tagging SNPs for GD-associated human leukocyte antigen (HLA) alleles in the Japanese population (HLA-DPB1*0501 and HLA-A*0206) demonstrated that all of and five of seven SNPs were not in strong LD with HLA-DPB1*0501 and HLA-A*0206, respectively. Although causal variants remain to be identified, our results demonstrate the existence of multiple GD susceptibility loci within the MHC region.
INTRODUCTION
Autoimmune thyroid disease (AITD), including Graves' disease (GD) and Hashimoto's thyroiditis (HT), is caused by immune response to self-thyroid antigens, and affects up to 2-5% of the general population. 1 GD is characterized by the production of thyroid-stimulating hormone receptor-stimulating antibodies, leading to hyperthyroidism, whereas HT is characterized by the apoptosis of the thyrocytes, resulting in hypothyroidism. 2, 3 Although the molecular mechanisms underlying the initiation of AITD remain largely elusive, twin studies and familial aggregation have clearly demonstrated the involvement of genetic factors with AITD in addition to environmental factors. 4, 5 Human leukocyte antigen (HLA)/major histocompatibility complex (MHC) locus on the chromosome 6p21 was the first region identified to be associated with AITD 25 years ago, and has been consistently replicated. However, the primary causal variant in this region remains still unknown due to the long extended linkage disequilibrium (LD) feature of the HLA region. 5, 6 Several AITD susceptibility genes from non-HLA loci have also been identified through candidate gene analyses and whole genome linkage studies, followed by locus-specific association analysis. Such non-HLA genes can be classified into at least two subgroups, thyroid-specific genes and immune-related genes. 6 The former group is comprised of the thyroglobulin gene (TG) 6 and TSHR. 7, 8 The latter group includes CTLA4, 9 FCRL3, 10 and PTPN22, 6 which are shown to be commonly involved in multiple autoimmune diseases. In addition to these genes, we have previously identified ZFAT (zinc-finger gene in AITD susceptibility region) on 8q24 as a susceptibility gene for both GD and HT, 11 and have revealed that ZFAT functions as a transcriptional regulator of immune-related genes. 12 Recent genome-wide association studies (GWAS) have dramatically increased the numbers of susceptibility loci of autoimmune diseases such as Crohn's disease, systemic lupus erythematosus and type-1 diabetes. 13 In contrast, there has been only one GWAS for GD in the Western population. 14 We conducted a two-stage GWAS to elucidate genetic variations involved in GD susceptibility in the Japanese population.
MATERIALS AND METHODS

Study participants
For the GWAS, we selected case-control samples (case 1, control 1, case 2 and control 2) from the subjects enrolled in the Biobank Japan. We selected cases from individuals registered as having GD, and controls from individuals with diseases other than autoimmune diseases including GD. For the first stage of GWAS, 195 individuals with GD (case 1) and 1362 control individuals (control 1) were enrolled. The female ratio and the mean ( ± s.d.) age of the case and control groups are: 67.2% and 47.7 (±15.7) for case 1, and 49.8% and 59.8 ( ± 12.2) for control 1. For the second stage of GWAS, 924 individuals with GD (case 2) and 1356 control individuals (control 2) were enrolled. The female ratio and the mean age of the groups are: 72.6% and 49.5 (±15.1) for case 2, and 39.0% and 61.2 (±18.6) for control 2. For the replication study, 432 individuals with GD (case 3) and 1157 control individuals (control 3) were enrolled. Diagnosis of GD was established as described previously. 15 Genomic DNA was isolated from peripheral blood cells using the QIAamp DNA blood Midi Kit (Qiagen, Tokyo, Japan). The ethical committees of all related institutes approved this study, and written informed consent was obtained from all subjects.
Genotyping and selection of SNPs
In the first stage of GWAS, 268 068 autosomal single nucleotide polymorphisms (SNPs), selected as described previously, 16 were genotyped using high-density oligonucleotide arrays (Perlegen Sciences, Mount View, CA, USA). The differences between the case and control groups (case 1 and control 1) with regard to the genotype distribution or the allele frequency were assessed by Fisher's exact test using dominant, recessive and allelic models. SNPs were ranked by the minimum P-value among three models. Top 4000 SNPs were considered to be subjected to the second stage of GWAS. In the second stage, genotyping was conducted using the multiplex-PCR invader assay as described previously. 17 Invader assays were successfully designed for approximately 3900 out of the top 4000 SNPs. A cohort of GD cases (case 2, n¼924) was genotyped by the invader assays for these 3900 SNPs. The obtained genotype data and those for a cohort of controls (control 2, n¼1356) by Perlegen arrays were subjected to association tests by Fisher's exact tests. The control 2 cohort was genotyped by invader assays for 2720 SNPs whose minimum P-value among three models (dominant, recessive and allelic) surpassed the significance threshold of Po10 À4 . After excluding 12 SNPs whose genotype counts of minor allele homozygotes include 0 in either of case 2 or control 2 cohort data, the remaining 2708 SNPs were subjected to statistical analyses to select GDassociated SNPs in the GWAS stage. In the replication study, genotyping was conducted using the TaqMan assay as described previously. 9 
Statistical methods
To select the GD-associated SNPs using the genome-wide screening data, a meta-analysis was performed for the integrated data set of the first and second GWAS stages, using the metafor package for R (http://www.wvbauer.com/ index.htm). In the meta-analysis, the I 2 metric 18, 19 was used to consider the extent of heterogeneity between the first and the second stages of GWAS: P-value of fixed-effects (Mantel-Haenszel) meta-analysis was adopted when I 2 metric is not larger than 50%, P-value of random-effects (DerSimonian-Laird) meta-analysis was adopted when I 2 metric is equal to or larger than 50%. In the replication study, disease associations were assessed by Cochran-Armitage trend test. Per allele odds ratios and their 95% confidence intervals were calculated using unconditional logistic regression. The thresholds for the Hardy-Weinberg equilibrium and minor allele frequency were set as P40.01 and 45%, respectively. SNPAlyze v7.0 software (DYNACOM, Mobara, Japan) and Haploview version 4.0 software 20 were used for LD calculation. Average power to detect common SNPs (risk allele frequency range of 0.1-0.9) that confer a genotype relative risk of 1.5 at GWAS stage 1 (195 cases versus 1362 controls) and replication stage was calculated, assuming an additive model in log-odds scale and GD population prevalence of 0.5%. The average power in the GWAS stage 1 was 68%. The average power in the replication study exceeded 80%.
GD cases and controls with missing genotype data regarding the SNPs to be analyzed are excluded in the following analyses. The multivariate stepwise logistic regression analysis was performed in a stepwise (forward-backward) manner to select SNPs that represented the GD risk within the MHC region. The entry and removal criteria with P-values of 0.01 based on the likelihood ratio test were used. To evaluate the ability of the seven-SNP-logistic regression model for phenotype prediction, a receiver-operating characteristic (ROC) analysis was conducted. A ROC curve to discriminate GD cases from healthy controls was generated using the combined data set, and the area under the curve was calculated.
To assess the cumulative effects of risk alleles at seven SNPs that were included in the logistic regression model, the risk score for each of the all possible seven-locus genotypes was calculated as described previously. 21 Subsequently, the frequencies of each of the combinations of the genotypes of the seven SNPs (790 combinations observed) in the GD and control populations in the combined data set of GWA and replication studies were determined.
RESULTS
To define genetic factors influencing the risk of GD in the Japanese population, we conducted a two-stage genome-wide association analysis in Japanese individuals with GD and unrelated controls. Characteristics of the cohort groups enrolled in each of the stages are described in the Materials and Methods section. In the first stage, we genotyped 268 042 autosomal SNPs, which covered approximately 56% of common SNPs in the Japanese, 16 in 195 individuals with GD (case 1) and 1362 unrelated controls (control 1) collected in the Biobank Japan. We subsequently assessed differences between the case and control groups with regard to genotype distribution or allele frequency by Fisher's exact test using dominant, recessive and allelic models. We ranked the genotyped SNPs by the minimum P-value among three models for each SNP and selected top 4000 SNPs showing the lowest P-values. As the second stage, we attempted to genotype these 4000 SNPs in 924 individuals with GD (case 2) and 1356 controls (control 2) by invader assays. After quality control processes as described in the Materials and Methods section, we successfully obtained genotyping data of 2708 SNPs to be subjected to association tests. Associations of these SNPs with GD were initially assessed by Cochran-Armitage trend test. The distribution of the test statistics for the SNPs in the second stage of GWAS was shown in Supplementary Figure S1 . Considering the well-established association of HLA genes with GD 5, 6 and the existence of multiple GD-associated SNPs in the MHC region revealed by the genome-wide analysis for the UK population, 14 we calculated the genomic inflation factor (lambda GC ) for the 2654 SNPs after excluding 54 SNPs located in the MHC region among the 2708 SNPs. The lambda GC for the 2654 SNPs was 1.088, suggesting that the data set was not heavily confounded by potential problems such as genotype misclassification or a population substructure.
Therefore, we tested for association between each SNP and GD by performing a meta-analysis of the results from the first and the second stages, and identified 34 SNPs (Supplementary Table S1 ) that surpassed the multiple-testing corrected significance threshold P c o1.86Â 10 À7 (0.05/268 042). Aside from two SNPs, rs2240306 located at the 5¢-upstream region of the SENP1 (sentrin/SUMO-specific protease 1) gene on chromosome 12, and rs1149386 located at the 3¢ downstream region of the SLAMF6 gene encoding an activating natural killer receptor precursor on chromosome 1, 32 out of 34 SNPs were located in an interval of 29.60-33.93 Mb within the MHC region on chromosome 6p21 (Figure 1 ). Replication of association of these 34 SNPs was tested in an independent set of cases and controls, comprising 432 Japanese individuals with GD (case 3) and 1157 controls (control 3), setting P c o0.00147 (0.05/34) for significant replication. This replication analysis identified significant association of 22 SNPs, all of which are located in the MHC region, with GD ( Table 1 ). All of these SNPs were in Hardy-Weinberg equilibrium in the controls (P40.019). The genotype counts and the statistics of the 12 SNPs that did not surpass the significance threshold in the replication study are listed in Supplementary Table S2 .
The MHC region is known to exhibit LD that extends across multiple HLA and non-HLA genes. 22 High-resolution LD mapping studies of the extended MHC region spanning about 7.6 Mb have revealed that LD exists in segments of over 2 Mb in some cases, but not all. Such studies have also demonstrated the existence of tight segment-to-segment LD observed between regions of strong LD that are located distantly from each other. 22, 23 We calculated the pairwise LD of the 22 SNPs that were found to be associated with GD, using the genotyping data of enrolled control sets (control 1+2+3, n¼3875). Among the 22 GD-associated SNPs, strong pairwise LD (r 2 40.8 and |D¢|40.9) was observed only within two pairs of closely located SNPs (SNPs #1/#2 and #6/#7, whose r 2 values are highlighted in red in the schematic LD patterns in Figure 1 ). Among the pairs of SNPs that are located distantly (4300 kb) from each other, only limited pairs exhibited modest or high levels (r 2 ¼0.21B0.51 and |D¢|¼0.50B0.90) of LD. These LD patterns observed among the 22 SNPs in the MHC region suggest that the detected association of these SNPs with GD cannot be explained by a segment of extensive long-range LD, but that, at least some SNPs are likely to represent genomic segments that contain independent risk factors of GD. As a statistical means to assess the independence of these 22 SNPs in terms of association with GD, we conducted association tests for these SNPs conditioned on rs2273017, which showed the lowest P-value in the unconditional association analysis. Genotype data of all GD cases (n¼1551) and controls (n¼3875) were subjected to the analysis. Significant association with GD (P c o0.00238 (0.05/21)) was detected for all SNPs (Supplementary Table S3 ), further indicating the independent involvement of multiple SNPs within the MHC region with GD. We subsequently conducted a multivariate stepwise logistic regression analysis to investigate the combinatorial effects of multiple SNPs with the risk of GD. Twenty out of 22 SNPs were subjected to the analysis as tagging SNPs (two SNPs, rs362540 and rs2254071 were excluded). GD cases and controls from GWAS and replication cohorts with genotypes for all 20 SNPs (GD, n¼1152; controls, n¼2570) were included in this analysis (as well as in the subsequent statistical analyses in this study). Consequently, we established a statistical model in which seven SNPs, rs3893464, rs4313034, rs3132613, rs4248154, rs2273017, rs9394159 and rs4713693, affected the risk of GD significantly and independently (Table 2 ). These seven SNPs are located discretely within a 4-Mb interval (Figure 1) .
We further evaluated the seven-SNP-logistic regression model for its ability to predict the disease status of GD in a given individual, using the combined data of the GWA and replication studies. When we calculated the risk score for each subject by summing the logarithm of the logistic regression-based odds ratio (Table 2) for each risk allele that he/she harbored, the observed GD risk showed a significant linear relationship with risk score (P¼2.1Â10 À44 , Table 3 ), indicating cumulative effects of the risk alleles for the seven SNPs on the development of GD. Compared with the subjects having zero to three risk alleles, the odds ratios of GD exceeded over fivefold in those having more than seven risk alleles, and over tenfold in those having more than 10 risk alleles (Table 3 and Supplementary Figure  S2) . The ROC curve of the seven-SNP-logistic regression model was generated to further assess its sensitivity and specificity of predicting the development of GD (Figure 2 ). The area under the ROC curve was 0.645, indicating a modest diagnostic ability of the model.
DISCUSSION
The MHC region represents one of the most extensively studied regions in the human genome because of the contribution of genetic variants in this region in autoimmune, infectious and inflammatory diseases. However, highly polymorphic nature and extensive LD of the MHC region has made it difficult to identify causal variants within this locus for the majority of diseases. 23 The Wellcome Trust Case Control Consortium (WTCCC) performed association scan of 14 436 non-synonymous SNPs and 897 MHC tag SNPs in four autoimmune diseases including GD. 14 In this WTCCC study, the strongest associations with GD were observed for SNPs in the MHC region. Although the maximum signal was observed around the MHC class I and class II genes, the strong association extended far beyond specific haplotypes. The International MHC Autoimmunity Genetics Network recently conducted an association analysis, using a panel of 1472 SNPs within the 3.44-Mb classic MHC region for a set of 10 576 DNA samples derived from patients with either of the seven immune-mediated diseases and appropriate control samples. 24 It should be noted that GD was not included in the seven diseases analyzed. This large-scale study has demonstrated that MHC associations with autoimmune diseases result from complex and multilocus effects that span the entire region.
We attempted to identify genetic variants involved in the risk of GD in the Japanese population by adopting a two-stage GWAS strategy. Whereas we detected strong association of multiple SNPs spanning several megabases within the MHC regions with GD, we failed to detect association of known and novel non-MHC loci with GD. We have previously reported that SNPs at ZFAT, CTLA4, FCRL3 and TSHR loci are associated with GD in the Japanese population. 7, [9] [10] [11] However, in this study, no SNP from these four loci, except for rs2210913 within the FCRL3 gene, was included in the top 4000 SNPs that were selected in the first stage of GWAS. SNP rs2210913 did not surpass the significance threshold in the meta-analysis of the results from the first and the second GWAS stages. It should be mentioned that the average power to detect common SNPs that confer a genotype relative risko1.5 did not exceed 80% in both of the current GWA and replication studies. Therefore, a lack of power to detect true association and an insufficient cover rate of the human genome in the first stage of GWAS in our study is likely to be mostly responsible for the discrepancy between the present results and past studies regarding the association of the genes located outside the MHC region with GD in the Japanese population. In the WTCCC study, although TSHR and FCRL3 loci were confirmed to be associated with GD, no additional locus was identified as a novel GD susceptibility locus. 14, 25 Through the GWA and the subsequent replication studies, we identified 22 GD-associated SNPs within the MHC region. Among them, seven SNPs that were integrated into the multivariate logistic were successfully genotyped, 1119 GD cases versus 2718 controls, meta-analysis P-values), the replication study (34 SNPs, 432 GD cases versus 1157 controls, Cochrane-Armitage trend P-values) and the combined analysis of both studies (22 SNPs, 1551 GD cases versus 3875 controls, Cochrane-Armitage trend P-values), respectively. The blue and light blue dashed-horizontal lines indicate the significance levels applied to the meta-analysis of the GWAS stages (a¼1.86Â10 À7 (0.05/268 042)) and applied to the association analysis in the replication study (a¼0.00147 (0.05/34)), respectively. Closed and open circles (blue and light blue) indicate P-values smaller than and the ones not smaller than the significance level applied, respectively. The rs IDs of the 22 SNPs, whose associations with GD were replicated, are listed below the P-value plot. Each SNP ID and the corresponding circles representing Àlog 10 (P) values are connected by a vertical dashed line. Seven SNPs shown in red correspond to the ones suggested to represent independent genetic risk factors of GD in the multivariate step-wise logistic regression analysis. Below the SNP IDs, pairwise linkage disequilibrium (LD) patterns of the 22 SNPs are schematically represented as a block structure. Genotype data of the controls (control 1, 2 and 3, n¼3875) were used to determine the pairwise LD coefficients D¢ and r 2 . In the schematic block for r 2 , red highlight denotes pairwise LD of r 2 X0.8, pink 0.84r 2 X0.5, right blue 0.44r 2 X0.2 and no highlight 0.24r 2 . In the schematic block for |D¢|, red highlight denotes pairwise LD of |D¢|X0.9, pink 0.94|D¢|X0.7 and no highlight 0.74|D¢|.
A GWAS for GD in Japanese population K Nakabayashi et al A GWAS for GD in Japanese population K Nakabayashi et al regression model were considered to represent seven independent GDrisk loci in the Japanese population. We assessed the implications of these findings for identification of individuals with GD before morbid events by evaluating the cumulative effects of risk alleles and conducting a ROC analysis. Although the identified GD-associated SNPs turned out to exhibit only a modest level of ability to predict the development of GD, the sensitivity/specificity could potentially be elevated by combining the information of GD-associated HLA alleles.
In the previous studies, HLA-A*0206 and HLA-DPB1*0501 have been reported to be associated with GD in the Japanese population. 26, 27 Because we did not genotype HLA alleles in this study, to assess the extent of LD between these HLA alleles and the Figure S2 . Figure 2 A receiver-operating characteristic (ROC) curve to discriminate GD cases from healthy controls.
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